Skip to content
‹ Back to IndustriesHealthcare

The Use of AI in Cancer Screenings

Medical imaging, an integral part of the cancer screening process, continues to experience rapid, year-over-year growth. Unfortunately, available radiologists cannot keep pace with the demand for their services fueled by the continued growth in cancer screening. New solutions are in desperate need to support diagnosis and improve workflows. Can AI play an important role in…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Medical imaging, an integral part of the cancer screening process, continues to experience rapid, year-over-year growth. Unfortunately, available radiologists cannot keep pace with the demand for their services fueled by the continued growth in cancer screening. New solutions are in desperate need to support diagnosis and improve workflows. Can AI play an important role in cancer screenings today and in the future? That’s what Health and Life Sciences at the Edge’s Tyler Kern wants to find out, and Intel’s Business Development and Sales Lead, Ryan Kim, and Lunit’s Director of INSIGHT Marketing, Jonathan Yang, have answers. 

The disparity between the growing need for cancer screenings and the radiologists available to do the work can lead to missed early detection of cancers on chest X-rays and mammograms. Yang says this situation can create a big problem. “Regarding mammography, a high number of screenings can be read as false-positive, meaning that only a single digit percent of those recalled are retested,” he explains. “So, this is where AI can come in. AI isn’t here to replace radiologists, but it is here to support them, especially regarding cancer screening.” Yang sees many potential benefits AI can provide in assisting cancer screenings for patients, physicians, and medical institutions.

AI-driven solutions can reduce physicians’ reading time. Yang states, “This allows physicians to spend more time on the hard and tough cases. It also enables early detection of disease.”

Integrating AI into the cancer screening process is a seamless process today. Yang says there are two ways to integrate AI into the diagnostic imaging workflow. The first is when an image is acquired, and the second is during the image interpretation process. In both cases, Luni partners with companies with imaging platforms to make the integration seamless for healthcare institutions.

The utilization of Intel’s OpenVINO™ Toolkit assists in processing images quickly and minimizing the time from X-ray imaging to diagnosis. With OpenVINO™ technology, diagnostics can run on a CPU-only mode of operations, which reduces the cost of operations while delivering on the imaging speed physicians need. 

Learn more about AI-enabled cancer screening solutions by connecting with Ryan Kim and Jonathan Yang on LinkedIn or visit Intel Health and Life Sciences and Lunit’s websites. 

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Network and Edge Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agreed to acquire most of Vantive's hemodialysis business for $125 million in base consideration, plus up to $45 million in contingent payments, with closing expected mid-2027. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility; the combined business could generate $400-450 million annually, depending on various factors.

  • 01Rockwell Medical acquires Vantive's hemodialysis concentrates, AK 98 machines, water treatment systems, and one-million-square-foot Medolla, Italy manufacturing campus for $125 million base price plus up to $45 million contingent on revenue and EBITDA milestones.
  • 02Combined business targeted to generate $400-450 million in annual revenue depending on operating performance, exchange rates, market conditions and integration.
  • 03Vantive's dialyzer portfolio, including Theranova dialyzer for expanded hemodialysis, remains with Vantive; the company will focus on home dialysis and critical care after divestiture.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512